Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis

Miodrag Gavrić; Svetlana Antić; Drago B. Jelovac; Anita I. Zarev; Milan B. Petrović; Mileta Golubović; Marija Antunović

doi:10.2298/3107

Miodrag Gavrić Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia
Svetlana Antić Institute of Radiology, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia
Drago B. Jelovac Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia
Anita I. Zarev Pharmacy „Viva B Plus“, Beograd, Serbia
Milan B. Petrović Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia
Mileta Golubović Clinical Center of Montenegro, Faculty of Medicine, Podgorica, Montenegro
Marija Antunović Clinical Center of Montenegro, Faculty of Medicine, Podgorica, Montenegro

DOI: https://doi.org/10.2298/3107

Keywords: diphosphonates, drug toxicity, osteonecrosis, jaw, tooth extraction,

Author Biographies

Miodrag Gavrić, Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia

chief of department, DDS, MD, dr Sci

Svetlana Antić, Institute of Radiology, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia

DDS,MSIV,phDstudent, resident

Drago B. Jelovac, Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia

DDS,MSII,MSci,resident

Anita I. Zarev, Pharmacy „Viva B Plus“, Beograd, Serbia

pharmacist

Milan B. Petrović, Clinic of Maxillofacial Surgery, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia

DDS,MD,PhD,maxillofacial surgeron

Mileta Golubović, Clinical Center of Montenegro, Faculty of Medicine, Podgorica, Montenegro

MD,PhD

Marija Antunović, Clinical Center of Montenegro, Faculty of Medicine, Podgorica, Montenegro

DDS,Oral surgeon, phD student

References

van Beek E, Hoekstra M, van de Ruit M, Löwik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994; 9(12): 1875−82.

Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of ac-tion of bisphosphonates. Cancer 2000; 88(12 Suppl): 2961−78.

Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gli-gorov J, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates. Crit Rev Oncol Hematol 2007; 64(3): 198−207.

Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhi-bition of protein prenylation by bisphosphonates causes sus-tained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006; 21(5): 684−94.

Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bis-phosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages. Curr Pharm Dess 2010; 16(27): 2950−60.

Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 2005; 328(1): 91−7.

Li B, Ling CJ, Wang X, Leong WF. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for os-teoporosis therapy. J Cell Biochem 2011; 112(5): 1229−42.

Sarin J, Derossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008; 14(3): 277−85.

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115−7.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36(3): 478−90.

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteo-necrosis of the Jaw - 2009 Update. Aust Endod J 2009; 35(3): 119−30.

Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg 2005; 63(11): 1567−75.

Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related os-teonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Path Oral Radiol Endod 2006; 102(4): 433−41.

Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 2009; 31(2): 202−6.

Chih-Hsueh L, Chiu-Shong L, Shih-Weli L. Long-term use oral bisphosphonate-related osteonecrosis of the jaw without dental extraction in elderly: A case repot. J Clin Gerontology Geriatrics 2011: 2(1): 30−2.

Kühl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphos-phonate-related osteonecrosis of the jaws--a review. Oral Oncol 2012; 48(10): 938−47.

Khan AM, Sindwani R. Bisphosphonate-related osteonecrosis of the skull base. Laryngoscope 2009; 119(3): 449−52.

Phillips JM, Thibodeaux JD, Nathan C. Skull Base Osteomyelitis and Bisphosphonate Use in Multiple Myeloma: Report of Two Cases and Literature Review. Laryngoscope 2010; 120(Suppl 4): S175.

Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2006; 132(1): 114.

Wernecke G, Namdari S, DiCarlo EF, Schneider R, Lane J. Case report of spontaneous, nonspinal fractures in a multiple mye-loma patient on long-term pamidronate and zoledronic acid. HSS journal 2008; 4(2): 123−7.

Granite EL. Are nitrogen-containing intravenous bisphos-phonates implicated in osteonecrosis of appendicular bones and bones other than the jaws? A survey and literature re-view. J Oral Maxillofac Surg 2012; 70(4): 837−41.

Yin G, Bai Y, Luo E. Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related os-teonecrosis of the jaw. Med Hipotheses 2011; 76(3): 347−9.

Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67(5 suppl): 61−70.

Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle. J Oral Maxillofac Surg 2010; 68(5): 1158−61.

Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes: in vitro study. Clin Oral Investig 2012; 16(1): 87−93.

Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncol-ogist 2012; 17(2): 279−87.

Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 2006; 288(12): 1243−9.

Allen MR. Burr DB. Mandible matrix necrosis in beagle dogs after three years of oral bisphosphonate treatment. J Oral Maxillofac Surg 2008; 6(5): 987−94.

Idris AI, Rojas J, Greig IR, Van HR, Ralston SH. Aminobis-phosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008; 82(3): 191−201.

Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of os-teoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009; 106(1): 109−18.

Subramanian G, Cohen HV, Quek SY. A model for the patho-genesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112(6): 744−53.

Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin On-col 2008; 26(24): 4037−8.

Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, et al. Osteoclasts are important for bone angiogene-sis. Blood 2010; 115(1): 140−9.

Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity. Bone 2007; 41(3): 318−20.

Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, et al- Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010; 68(11): 2837−45.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin In-vest 1991; 88(6): 2095−105.

Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010; 38(4): 255−9.

Sedghizadeh PP, Yooseph S, Fadrosh DW, Zeigler-Allen L, Thiaga-rajan M, Salek H, et al. Metagenomic investigation of micro-bes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy. Oral Surg Oral Med Oral Pa-thol Oral Radiol 2012; 114(6): 764−70.

Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; (20 Suppl 4): 137−9.

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20(1): 117−20.

Malan J, Ettinger K, Naumann E, Beirne RO. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114(6): 671−6.

Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2(1): 7−14.

Broćić M, Kozomara R, Cerović S, Jović N, Vukelić-Marković S, Stosić S. Clinical significance of vascular endothelial growth factor expression in patients with carcinoma of the mouth floor and tongue. Vojnosanit Pregl 2009; 66(6): 440−8.

Golubović M, Petrović M, Jelovac DB, Nenezić DU, Antunović M. Malignant ameloblastoma metastasis to the neck: radiological and pathohistological dilemma. Vojnosanit Pregl 2012; 69(5): 444−8.